<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02346890</url>
  </required_header>
  <id_info>
    <org_study_id>D5611C00006</org_study_id>
    <nct_id>NCT02346890</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722</brief_title>
  <official_title>A Phase 1, Single-center, Randomized, 2-way Crossover, Open Label Study to Evaluate the Effect of Renvela on the Pharmacodynamics of AZD1722 in Healthy Volunteeers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardelyx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardelyx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics
      of AZD1722 in healthy volunteers taking Renvela.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sodium levels in stool and urine</measure>
    <time_frame>4 days</time_frame>
    <description>Pharmacodynamic activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of AZD1722, measured by Adverse events</measure>
    <time_frame>8 days</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the safety of AZD1722, measured by clinical laboratory changes</measure>
    <time_frame>8 days</time_frame>
    <description>clinical laboratory changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma drug concentration to calculate AUC</measure>
    <time_frame>8 days</time_frame>
    <description>Evaluate the Pharmacokinetics of AZD1722</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>AZD1722 alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD1722 with Renvela</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1722 15 mg BID and Renvela 800 mg TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1722</intervention_name>
    <arm_group_label>AZD1722 alone</arm_group_label>
    <arm_group_label>AD1722 with Renvela</arm_group_label>
    <other_name>RDX5791</other_name>
    <other_name>Tenapanor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renvela</intervention_name>
    <arm_group_label>AD1722 with Renvela</arm_group_label>
    <other_name>Sevelamer carbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy man or woman

          -  Body mass index between 18 and 29.9 kg/m2

        Exclusion Criteria:

          -  Diagnosis or treatment of any clinically symptomatic biochemical or structural
             abnormality of the gastrointestinal (GI) tract

          -  Any surgery on the small intestine or colon, excluding appendectomy or cholecystectomy
             or any other condition known to interfere with absorption, distribution, metabolism or
             excretion of drugs

          -  Clinical evidence of significant cardiovascular, respiratory, renal, hepatic,
             gastrointestinal, hematologic, metabolic, endocrine, neurologic, psychiatric disease,
             or any condition that may interfere with the subject successfully completing the trial
             or that would present a safety risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P Rosenbaum, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ardelyx, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>January 26, 2015</last_update_submitted>
  <last_update_submitted_qc>January 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

